SC
ADMA icon

Scotia Capital’s ADMA Biologics ADMA Stock Holding History

Scotia Capital’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,150
Closed -$283K – 857
2024
Q3 		$283K Buy
+14,150
New +$220K ﹤0.01% 704

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Scotia Capital's ADMA Position: Q4 2024 in Review

Scotia Capital sold out of ADMA Biologics (ADMA) in Q4 2024, closing a stake of 14,150 shares — an estimated $283K sold.

Scotia Capital first reported a position in ADMA in Q3 2024 and held it in 1 quarter. The position peaked at $283K in Q3 2024. 322 funds tracked by Wall St. Rank hold ADMA as of Q4 2024.

  • Scotia Capital reported no remaining ADMA Biologics position as of Q4 2024 after selling out during the quarter.
  • Scotia Capital sold 14,150 ADMA Biologics shares in Q4 2024, an estimated $283K.
  • Scotia Capital first reported a position in ADMA Biologics in Q3 2024 and held it in 1 quarter.
  • Scotia Capital's ADMA Biologics position peaked at $283K in Q3 2024.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2024.

Based on Scotia Capital's 13F filing for Q4 2024, filed 13 Feb 2025.